Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA

被引：1

作者：

Parren, Paul W. H. I. ^{[1
,2
]}

Burton, Dennis R. ^{[3
]}

Bradbury, Andrew ^{[4
]}

Huston, James S. ^{[5
]}

Carter, Paul J. ^{[6
]}

Veldman, Trudi ^{[7
]}

Chester, Kerry A. ^{[8
]}

Larrick, James W. ^{[9
,10
]}

Alfenito, Mark R. ^{[11
]}

Scott, Jamie K. ^{[12
]}

Weiner, Louis M. ^{[13
]}

Adams, Gregory P. ^{[14
]}

Reichert, Janice M. ^{[15
]}

机构：

[1] Genmab, Utrecht, Netherlands

[2] Leiden Univ, Med Ctr, Leiden, Netherlands

[3] Scripps Res Inst, La Jolla, CA 92037 USA

[4] Los Alamos Natl Lab, Los Alamos, NM USA

[5] Huston BioConsulting LLC, Newton Lower Falls, MA USA

[6] Genentech Inc, San Francisco, CA 94080 USA

[7] AbbVie, Worcester, MA USA

[8] UCL, London, England

[9] Panorama Res Inst, San Francisco, CA USA

[10] Veloc Pharmaceut Dev, San Francisco, CA USA

[11] EnGen Bio Inc, San Mateo, CA USA

[12] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada

[13] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

[14] Viventia Bio Inc, Philadelphia, PA USA

[15] Reichert Biotechnol Consulting LLC, Framingham, MA 01701 USA

来源：

MABS | 2015年 / 7卷 / 06期

关键词：

antibody engineering; antibody-drug conjugates; antibody repertoire; bispecific antibodies; computational design; next-generation sequencing; reproducibility;

D O I：

10.1080/19420862.2015.1089707

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society, will be held in San Diego, CA in early December 2015. In this meeting preview, the chairs provide their thoughts on the importance of their session topics, which include antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, overcoming resistance to clinical immunotherapy, and building comprehensive IGVH-gene repertoires through discovering, confirming and cataloging new germline IGVH genes. The Antibody Society's special session will focus on Antibodies to watch in 2016, which are a subset of the nearly 50 antibodies currently in Phase 3 clinical studies. Featuring over 100 speakers in total, the meeting will commence with keynote presentations by Erica Ollmann Saphire (The Scripps Research Institute), Wayne A. Marasco (Dana-Farber Cancer Institute/Harvard Medical School), Joe W. Gray (Oregon Health & Science University), and Anna M. Wu (University of California Los Angeles), and it will conclude with workshops on the promise and challenges of using next-generation sequencing for antibody discovery and engineering from synthetic and in vivo libraries and on computational antibody design.

引用

页码：981 / 988

页数：8